RECEIVED CENTRAL FAX CENTER

Serial No. 10/645,784

JUN L3 Zuuß

REMARKS/ARGUMENTS

Claims 29, 46 to 51, and 63 to 68 are currently pending. Claim 46 is amended hereby.

The amendment to the claims reflects the substance of the conversations between the examiner and the applicants' attorney on May 30th and June 2nd, 2008. The amendment to claim 46 is consistent with the process as shown in Figure 1 as well as in the Summary of the Invention (see page 11, line 16 to page 12, line 6).

The amendment to Claim 46 also makes clear the relation of the steps of the claimed process. The peptide sequences in step (a) correspond to the P1, P2, P3, and P4 substituents in the formula shown in step (b). The process has been successfully carried out, as described in U.S. Pat. No. 7,259,137, issued August 21, 2007. Although the patent refers to binding to TALL-1, the specification makes clear that AGP-3 is an alternate name for TALL-1 (col. 2, lines 1-15; see also col. 8, line 46 to col. 9, line 37 and col. 53, line 60 to col. 58, line 6, in which the AGP-3 name is used).

In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments and allowance of all claims.

Respectfully submitted,

Attorney for Applicants

Registration No.: 33,111 Phone: (805) 447-2688

Date: June 3, 2008

Please send all future correspondence to: **US Patent Operations/TJG** M/S 28-2-C AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799